Restore dopamine to improve walking
- Trial ID
- NCT05901818
- Official Title
- Safety and Efficacy of Autologous Induced Neural Stem Cell-derived Dopaminergic Precursor Cells in the Treatment of Parkinson's Disease
- Goal
- Restore dopamine to improve walking
- Phase
- PHASE1
- Status
- RECRUITING
- Sponsor
- Xuanwu Hospital, Beijing
- Study Type
- INTERVENTIONAL
- Enrollment
- 10 participants
- Conditions
- Parkinson's Disease
- Interventions
- Autologous induced neural stem cell-derived DA precursor cells
Plain-Language Summary
They want to see if transplanting a patient’s own reprogrammed neural stem cells can safely replace the dopamine-producing neurons lost in Parkinson's, with the hope of improving movement and lowering medication needs. The team makes induced neural stem cells from the patient, grows them into dopaminergic precursor cells, and implants them into the brain so they can survive, make dopamine, and integrate into circuits; because the cells come from you there is less risk of immune rejection, and patients will initially stay on levodopa while doctors watch how the graft affects symptoms and medication. Enrollment is for people aged 30 to 85 who have had Parkinson's for more than 3 years, are Hoehn and Yahr stage 4 or less when medicated, and show at least a 30% motor improvement with levodopa. People with atypical or secondary parkinsonism, major other brain or systemic illnesses, significant cognitive impairment, severe dyskinesia, prior brain surgery, long-term anticoagulant use, MRI or PET contraindications, or pregnancy are excluded.
Locations
- Xuanwu Hospital Capital Medical University, Beijing, Beijing Municipality, China
Frequently Asked Questions
- What is this trial testing?
- This trial is studying Autologous induced neural stem cell-derived DA precursor cells. They want to see if transplanting a patient’s own reprogrammed neural stem cells can safely replace the dopamine-producing neurons lost in Parkinson's, with the hope of improving movement and lowering medication needs. The team makes induced neural stem cells from the patient, grows them into dopaminergic precursor cells, and implants them into the brain so they can survive, make dopamine, and integrate into circuits; because the cells come from you there is less risk of immune rejection, and patients will initially stay on levodopa while doctors watch how the graft affects symptoms and medication. Enrollment is for people aged 30 to 85 who have had Parkinson's for more than 3 years, are Hoehn and Yahr stage 4 or less when medicated, and show at least a 30% motor improvement with levodopa. People with atypical or secondary parkinsonism, major other brain or systemic illnesses, significant cognitive impairment, severe dyskinesia, prior brain surgery, long-term anticoagulant use, MRI or PET contraindications, or pregnancy are excluded.
- Who can participate?
- Participants must be between 30 Years and 85 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This Phase 1 trial is estimated to last approximately 2 years and 7 months.